SEHK:1952
SEHK:1952Biotechs

Everest Medicines (SEHK:1952) Is Down 7.0% After Striking First Ophthalmology Deal With Visara Inc

On October 28, 2025, Everest Medicines Limited announced it had entered into an exclusive licensing agreement with Visara Inc. to develop, manufacture, and commercialize VIS-101, a novel bifunctional biologic for wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion, in Greater China, Singapore, South Korea, and select Southeast Asian countries, with upfront, milestone, and royalty payments totaling up to US$89 million plus additional expenses. This...
SEHK:700
SEHK:700Interactive Media and Services

The Bull Case For Tencent Holdings (SEHK:700) Could Change Following Easing China Trade Tensions and Improved Inflation Data

In recent days, Tencent Holdings shares moved higher following positive macroeconomic developments in China, including easing trade tensions, the lifting of certain export curbs, and encouraging inflation data. An interesting aspect is that this optimism in the Chinese technology sector also impacted Prosus, a major shareholder with a significant stake in Tencent Holdings. We'll now explore how renewed investor confidence amid easing trade tensions may influence Tencent's investment outlook...
SEHK:1318
SEHK:1318Personal Products

Asian Stocks Estimated To Be Up To 38.1% Below Intrinsic Value

As global markets face challenges such as AI valuation concerns and economic uncertainties, Asian stocks have shown resilience with some indices reaching new highs. In this environment, identifying undervalued stocks becomes crucial, as they may offer potential opportunities for investors seeking to capitalize on discrepancies between market price and intrinsic value.
SEHK:340
SEHK:340Metals and Mining

Asian Penny Stocks To Watch In November 2025

Amid the evolving global economic landscape, Asian markets have shown resilience, with Chinese indices experiencing gains due to easing trade tensions. In this context, penny stocks—often smaller or newer companies—remain a noteworthy investment area despite their historical connotations. These stocks can offer a unique blend of affordability and growth potential when backed by strong financials, making them intriguing options for investors seeking opportunities beyond mainstream equities.
SEHK:1109
SEHK:1109Real Estate

How Investors May Respond To China Resources Land (SEHK:1109) After Hong Kong’s Economic Rally and Trade Truce

In recent days, Hong Kong’s economy has shown resilience with 3.8% GDP growth and rising retail sales, providing support to key developers like China Resources Land. A recent U.S.-China trade truce and tariff reductions offer further relief to companies involved in cross-border property markets, even as China faces manufacturing headwinds. To assess what this means for China Resources Land, we’ll explore how Hong Kong’s strong economic performance influences the company’s investment...
SEHK:1199
SEHK:1199Infrastructure

COSCO SHIPPING Ports (SEHK:1199): Valuation Insights Following Strong Nine-Month Earnings Growth

COSCO SHIPPING Ports (SEHK:1199) released its third quarter and nine-month earnings, drawing attention for showing higher sales and net income compared to last year. Investors are likely watching to see how these stronger results play out. See our latest analysis for COSCO SHIPPING Ports. The recent bump in nine-month earnings has come as COSCO SHIPPING Ports' share price has gained steady ground, up 29.3% year-to-date and closing at $5.91. With a 43.6% total return for the year, the stock's...
SEHK:9995
SEHK:9995Biotechs

RemeGen (SEHK:9995) Valuation in Focus After Sales Growth and Positive Telitacicept Trial Results

RemeGen (SEHK:9995) just posted stronger sales numbers and trimmed its net loss for the first nine months of 2025. At the same time, new study results for its telitacicept drug are bolstering investor confidence. See our latest analysis for RemeGen. RemeGen’s stock has been volatile but delivered impressive gains for investors this year, with the share price up 524% year-to-date and a one-year total shareholder return of nearly 340%. After spiking sharply on optimism about its clinical...
SEHK:9966
SEHK:9966Biotechs

Can Alphamab Oncology’s (SEHK:9966) FDA Fast Track Milestone Reshape Its Competitive Position in Oncology?

Alphamab Oncology recently announced that its drug candidate JSKN003 has received Fast Track Designation from the U.S. FDA for the treatment of platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer, without restriction by HER2 expression. This regulatory milestone builds on promising international clinical trial data and highlights momentum in Alphamab's pipeline of antibody-based oncology therapies. We'll explore how the U.S. FDA's Fast...
SEHK:2669
SEHK:2669Real Estate

Could Management Changes at China Overseas Property (SEHK:2669) Shift the Company’s Long-Term Strategic Focus?

China Overseas Property Holdings Limited announced that, following a board meeting on October 28, 2025, Mr. Pang Jinying resigned from his roles as Executive Director, Vice President, and alternate to the authorised representative due to a realignment of work duties. This departure marks a significant leadership transition and raises important considerations about continuity in management and overall corporate governance. We will assess how this key executive change could influence investor...